BIG PHARMA SPLIT CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.4 CAD | +0.70% |
|
+2.93% | +4.73% |
| Apr. 23 | Big Pharma Split Corp. Declares April 2024 Distribution, Payable on May 9, 2024 | CI |
| Mar. 29 | Big Pharma Split Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 16.83 | 14.87 | 12.53 | 19.37 | 22.08 | 16.76 |
| Enterprise Value (EV) 1 | 29.83 | 24.91 | 21.64 | 32.8 | 31.11 | 26.86 |
| P/E ratio | 7.96 x | 6.51 x | -61.4 x | 4.49 x | 9.21 x | -25.9 x |
| Yield | 9.99% | - | - | 8.43% | 8.49% | 9% |
| Capitalization / Revenue | 2.64 x | 6.2 x | 17.6 x | 3.48 x | 3.32 x | 52.3 x |
| EV / Revenue | 4.67 x | 10.4 x | 30.5 x | 5.9 x | 4.68 x | 83.7 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | 6.38 x | -42.7 x | -356 x | 17.9 x | -22.4 x | 6.57 x |
| FCF Yield | 15.7% | -2.34% | -0.28% | 5.58% | -4.47% | 15.2% |
| Price to Book | 0.88 x | 0.91 x | 0.95 x | 0.97 x | 0.95 x | 1.01 x |
| Nbr of stocks (in thousands) | 1,360 | 1,058 | 935 | 1,320 | 1,514 | 1,219 |
| Reference price 2 | 12.38 | 14.05 | 13.40 | 14.67 | 14.58 | 13.75 |
| Announcement Date | 3/28/19 | 4/1/20 | 3/29/21 | 3/30/22 | 3/30/23 | 3/29/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 6.386 | 2.399 | 0.7099 | 5.562 | 6.649 | 0.3208 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | 5.66 | 1.764 | 0.1862 | 4.606 | 5.762 | -0.3632 |
| Operating Margin | 88.62% | 73.54% | 26.23% | 82.81% | 86.67% | -113.22% |
| Earnings before Tax (EBT) 1 | 2.105 | 2.58 | -0.2174 | 4.21 | 2.389 | -0.6454 |
| Net income 1 | 2.105 | 2.58 | -0.2174 | 4.21 | 2.389 | -0.6454 |
| Net margin | 32.96% | 107.56% | -30.62% | 75.69% | 35.94% | -201.16% |
| EPS 2 | 1.556 | 2.157 | -0.2183 | 3.265 | 1.583 | -0.5303 |
| Free Cash Flow 1 | 4.677 | -0.5829 | -0.0607 | 1.829 | -1.39 | 4.086 |
| FCF margin | 73.24% | -24.3% | -8.56% | 32.89% | -20.91% | 1,273.57% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | 222.21% | - | - | 43.45% | - | - |
| Dividend per Share 2 | 1.237 | - | - | 1.237 | 1.237 | 1.237 |
| Announcement Date | 3/28/19 | 4/1/20 | 3/29/21 | 3/30/22 | 3/30/23 | 3/29/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 13 | 10 | 9.12 | 13.4 | 9.04 | 10.1 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 4.68 | -0.58 | -0.06 | 1.83 | -1.39 | 4.09 |
| ROE (net income / shareholders' equity) | 11.2% | 14.7% | -1.47% | 23.7% | 11.3% | -3.63% |
| ROA (Net income/ Total Assets) | 10.7% | 3.63% | 0.46% | 9.48% | 9.37% | -0.69% |
| Assets 1 | 19.67 | 71.15 | -46.81 | 44.42 | 25.51 | 93.29 |
| Book Value Per Share 2 | 14.10 | 15.40 | 14.10 | 15.10 | 15.40 | 13.60 |
| Cash Flow per Share 2 | 0.3100 | 0.5100 | 0.2500 | 0.9600 | 0.6400 | 0.1800 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/28/19 | 4/1/20 | 3/29/21 | 3/30/22 | 3/30/23 | 3/29/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +4.73% | 12.22M | |
| +1.77% | 492M | |
| +7.00% | 241M | |
| +37.19% | 231M | |
| +20.90% | 196M | |
| +12.53% | 116M | |
| +1.83% | 84.58M | |
| -13.37% | 52.14M |
- Stock Market
- Equities
- PRM Stock
- Financials Big Pharma Split Corp.
